Stock Market Reviews

IFRX (InflaRx N.V.) News

Get the latest news, insights, and market updates on IFRX (InflaRx N.V.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference
  InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. CEO Niels C. Riedemann said the company has recently streamlined its corporate strategy to
  Feb 26, 2026 - $IFRX
• InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
  JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the
  Feb 26, 2026 - $IFRX
• InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
  InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus
  Feb 14, 2026 - $IFRX
• Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
  Just because a business does not make any money, does not mean that the stock will go down. For example, although...
  Feb 2, 2026 - $IFRX
• InflaRx Announces Participation in February Investor Conferences
  JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows: Guggenheim Securities Emerging Outlook: Biotech Summit 2026February 11 - 12, 2026 in New York, NYFireside chat on Wednesday, February 11 at 11:30 AM ET InflaRx will also conduct one-on-one investor meetings
  Jan 29, 2026 - $IFRX
• InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
  InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographiesToward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaR
  Jan 8, 2026 - $IFRX
• InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
  While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effectInflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in co
  Dec 30, 2025 - $IFRX
• InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
  JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonpropriet
  Dec 11, 2025 - $IFRX
• Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
  The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio
  Nov 18, 2025 - $IFRX
• InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in Phase 2a Study—What's Changed
  InflaRx recently announced positive topline data from its Phase 2a basket study of oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, with rapid and durable improvements in clinical endpoints and no serious adverse events reported. An interesting insight is that efficacy measures for INF904 compared favorably with those of currently approved therapies, with continued benefits seen even after treatment ended. We'll explore how these promising efficacy...
  Nov 13, 2025 - $IFRX